Sensible Medical Innovations Company

"Noninvasive Lung Fluid Monitoring and Management."

Sensible Medical Innovations has developed the ReDS medical radar technology, which originated from the defense industry’s “see through walls” technology. ReDS is designed to monitor and manage patients with fluid management problems, including patients living with heart failure (HF), taking diuretic medication, or recovering from an event related to coronary artery disease.
ReDS is intended for use by qualified healthcare practitioners and by patients under the direction of a physician in hospitals, hospital-type facilities, and the home environment. In a pilot study, ReDS-guided HF management reduced the number of HF-related rehospitalizations by approximately 80%.
The company is headquartered in Israel with commercial offices in the United States. In August 2015, Sensible Medical’s noninvasive thoracic fluid status monitor was cleared for market in the United States.

Combating Coronavirus Pandemic:
Sensible Medical Innovations's solution helps address the Coronavirus Pandemic.
Technology: COVID Treatments
Industry: HealthTech
Headquarters: Israel
Founded Date: 2007
Employees Number: N/A
Funding Status: N/A

Visit Website
Register and Claim Ownership